ResearcherChulalongkorn UniversityActive in the last 2 years
Phonthep Angsuwatcharakon
Matched on ORCID iD 0000-0001-6924-2794; OpenAlex author ID A5033459564. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers
Papers 5
- One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation. Co-author DOI 10.1016/j.gie.2025.06.008↗
- Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2535-7440↗
- Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2571-2951↗
- EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observational open-label pilot study. Co-author DOI 10.1097/eus.0000000000000003↗
- Identification of Pancreatic Cancer in Biliary Obstruction Patients by FRY Site-specific Methylation. Co-author PMID 27797266↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Pradermchai Kongkam · 5 shared papers, 2016–2025 · strength 0.92
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Rungsun Rerknimitr · 5 shared papers, 2016–2025 · strength 0.92
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Parit Mekaroonkamol · 3 shared papers, 2025 · strength 0.70
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Thaninee Prasoppokakorn · 2 shared papers, 2025 · strength 0.49
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Roongruedee Chaiteerakij · 2 shared papers, 2025 · strength 0.49
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Nipan Israsena · 2 shared papers, 2025 · strength 0.49
- Paper Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III pancreatic ducta… DOI 10.1055/a-2535-7440↗
- Paper Correction: Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I-III panc… DOI 10.1055/a-2571-2951↗
- Pinit Kullavanijaya · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Kasenee Tiankanon · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Thanawat Luangsukrerk · 2 shared papers, 2023–2025 · strength 0.37
- Paper One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequenc… DOI 10.1016/j.gie.2025.06.008↗
- Paper EUS-guided radiofrequency ablation plus chemotherapy versus chemotherapy alone for pancreatic cancer (ERAP): An observa… DOI 10.1097/eus.0000000000000003↗
- Dong Wan Seo · 1 shared paper, 2023 · strength 0.16
- Apiwat Mutirangura · 1 shared paper, 2016 · strength 0.06
- Ratakorn Srisuttee · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.